Table 1

Baseline patient characteristics

IDDiagnosisHistology detailsAgeSexYears with cancerPrevious lines of therapy
1Colon cancerMucusal AC, KRASmut65F6.32
2Colon cancerAC, KRASmut, MSI-low,63M2.93
3Colon cancerAC, KRASmut, MSI-low55F5.12
4Colon cancerAC, MSS57F12.34
5Colon cancerAC, BRAFmut44M1.22
6Rectal cancerAC, KRASmut, MSS53F3.32
7Rectal cancerAC, MSS45M2.44
8CCChronic inflammation66F3.92
9CCFGFR fusion54F13.110*
11Melanoma (skin)PD-L1neg, BRAFwt46M2.91†
12Melanoma (skin)PD-L1neg, BRAFmut51F8.43†
13Melanoma (choridea)BRAFwt47F4.92*
14Melanoma (choridea)BRAFwt39M12.94*
15Melanoma (choridea)63F3.91*
16Melanoma (choridea)BRAFwt55M1.22†
18LeiomyosarcomaLiver-derived, grade 351M5.11
19Oropharyngeal cancer (HNSCC)SCC, P16+57M5.32*
20Cervix cancerSCC, P16+, P40+40F9.55*
21Myoepithelial carcinomaPD-L1neg65M2.71
22AdrenocorticocarcinomaWeiss score 964F0.91
23Non-small cell lung cancerAC, PD-L1neg45F64
24Rhinopharyngeal cancerLow diff.43F4.52
25Thyroid cancerLow diff.57M4.33
  • Overview of all patients treated with adoptive cell therapy in the clinical trial.

  • *Included anti-PD-1/PD-L1.

  • †Included anti-PD-1 and anti-CTLA-4.

  • AC, adenocarcinoma; CC, cholangiocarcinoma; F, female; FGFR, fibroblast growth factor receptor; HNSCC, head-and-neck squamous cell carcinoma; M, male; MSI, microsatelite instability; MSS, microsatelite stability; SCC, squamous cell carcinoma.